Shots:
J&J has entered into a definitive agreement to acquire Firefly Bio, incl. its Firelink degrader antibody conjugate (DAC) platform, expanding its oncology pipeline
As per the deal, J&J will acquire Firefly Bio for $1B in cash, with closing expected later this year
The Firelink DAC platform is a targeted protein degradation tech that selectively…
